Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / KEM - KEMET Announces Fourth Quarter and Fiscal Year Results


KEM - KEMET Announces Fourth Quarter and Fiscal Year Results

FORT LAUDERDALE, Fla., May 14, 2020 (GLOBE NEWSWIRE) -- KEMET Corporation (the “Company”) (NYSE: KEM), a leading global supplier of electronic components, today reported preliminary results for the fourth quarter and fiscal year ended March 31, 2020.

Fourth Quarter Highlights

  • Net sales of $293.2 million
  • GAAP gross margin of 31.4% and non-GAAP adjusted gross margin of 31.9%
  • GAAP EPS net loss of $0.01 per diluted share
  • Non-GAAP adjusted EPS of $0.37 per diluted share

Full Year Highlights

  • Net sales of $1.26 billion
  • GAAP gross margin of 33.4% and non-GAAP adjusted gross margin of 33.7%
  • GAAP EPS of $0.70 per diluted share
  • Non-GAAP adjusted EPS of $2.31 per diluted share

“During these unprecedented times, our number one priority remains the safety and well-being of our employees, their families, and the communities in which we operate. I am proud of our colleagues around the world who have worked together to quickly implement COVID-19 prevention actions sooner than required by federal or local governments to keep our employees safe and our facilities operating while continuing to serve critical infrastructure customers who need our products,” stated William M. Lowe Jr., KEMET’s Chief Executive Officer. “Despite COVID-19’s global impact, I am pleased to report that KEMET's fourth quarter results exceeded our revenue guidance, as we finished the quarter with $293.2 million in revenue and with non-GAAP adjusted gross margin and adjusted EBITDA margin of 31.9% and 18.5% respectively. This reinforces the fact that the structural changes we have made in our operations are firmly ingrained in our margin structure. While estimating the full impact the global COVID-19 pandemic will have on our upcoming fiscal year remains very challenging, we continue to believe at this time that our robust financial position will see us through the storm and position us well for long term growth. We now expect our combination with Yageo to close this summer,” continued Lowe.

For the quarter and fiscal year ended March 31, 2020, net sales were $293.2 million and $1.26 billion, respectively, compared to $355.8 million and $1.38 billion, respectively, for the same period last year.

GAAP gross margin for the quarter ended March 31, 2020 was 31.4% compared to 35.5% for the quarter ended March 31, 2019. Non-GAAP adjusted gross margin for the quarter ended March 31, 2020 was 31.9% compared to 34.8% for the quarter ended March 31, 2019.

GAAP gross margin for the fiscal year ended March 31, 2020 was 33.4% compared to 33.2% for the fiscal year ended March 31, 2019. Non-GAAP adjusted gross margin for the fiscal year ended March 31, 2020 was 33.7% compared to 33.3% for the fiscal year ended March 31, 2019.

GAAP net loss was $0.3 million or $0.01 per diluted share for the quarter ended March 31, 2020, compared to GAAP net income of $93.4 million or $1.58 per diluted share for the quarter ended March 31, 2019.

GAAP net income was $41.4 million or $0.70 per diluted share for the fiscal year ended March 31, 2020, compared to GAAP net income of $206.6 million or $3.50 per diluted share for the fiscal year ended March 31, 2019.

GAAP net income (loss) for the quarter and fiscal year ended March 31, 2020 included $17.6 million and $19.7 million in losses related to the write down of long-lived assets. GAAP net income for the quarter and fiscal year ended March 31, 2019 included a tax benefit of $50.1 million related to the partial release of valuation allowances in the U.S. and Japan. The one-time net income benefit of this release was a result of the significant improvements in our profitability of the past several years and the expectation of continued profitability in the future.

Non-GAAP adjusted net income was $22.2 million or $0.37 per diluted share for the quarter ended March 31, 2020, compared to non-GAAP adjusted net income of $61.4 million or $1.04 per diluted share for the quarter ended March 31, 2019.

Non-GAAP adjusted net income was $137.3 million or $2.31 per diluted share for the fiscal year ended March 31, 2020, compared to non-GAAP adjusted net income of $207.1 million or $3.51 per diluted share for the fiscal year ended March 31, 2019.

Net income for the quarter and fiscal year ended March 31, 2020, December 31, 2019, and March 31, 2019, include various items affecting comparability as denoted in the GAAP to non-GAAP reconciliation table included hereafter.

Presentation of Non-GAAP Financial Measures

The Company has presented certain historical financial measures that have not been prepared in accordance with GAAP, including adjusted gross margin, adjusted net income, adjusted earnings per share, and adjusted EBITDA margin. Definitions of our non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this news release.

About KEMET

The Company’s common stock is listed on the NYSE under the ticker symbol “KEM” (NYSE: KEM). At the Investor Relations section of our web site at http://www.kemet.com/IR, users may subscribe to KEMET news releases and find additional information about our Company. KEMET offers our customers the broadest selection of capacitor technologies in the industry, along with an expanding range of sensors, actuators, and electromagnetic compatibility solutions. KEMET operates manufacturing facilities and sales and distribution centers around the world. Additional information about KEMET can be found at http://www.kemet.com.

Cautionary Statement on Forward-Looking Statements

Certain statements included herein contain forward-looking statements within the meaning of federal securities laws about the Company's financial condition and results of operations that are based on management's current expectations, estimates and projections about the markets, in which the Company operates, as well as management's beliefs and assumptions. Words such as "expects," "anticipates," "believes," "estimates" or other similar expressions and future or conditional verbs such as “will,” “should,” “would,” and “could” are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's judgment only as of the date hereof. The Company undertakes no obligation to update publicly any of these forward-looking statements to reflect new information, future events or otherwise.

Factors that may cause actual outcomes and results to differ materially from those expressed in, or implied by, these forward-looking statements include, but are not necessarily limited to, the following: (i) the failure to complete the merger with Yageo Corporation (the “Merger”) and the effects such failure would have on the Company's financial condition and results of operations, (ii) certain business uncertainties and contractual restrictions related to the pendency of the Merger, (iii) our inability to pursue alternatives to the Merger during the pendency of the Merger, (iv) adverse economic conditions could impact our ability to realize operating plans if the demand for our products declines, and such conditions could adversely affect our liquidity and ability to continue to operate and could cause a write down of long-lived assets or goodwill; (v) an increase in the cost or a decrease in the availability of our principal or single-sourced purchased raw materials; (vi) changes in the competitive environment; (vii) uncertainty of the timing of customer product qualifications in heavily regulated industries; (viii) economic, political, or regulatory changes in the countries in which we operate; (ix) difficulties, delays, or unexpected costs in completing the Company’s restructuring plans; (x) acquisitions and other strategic transactions expose us to a variety of risks, including the ability to successfully integrate and maintain adequate internal controls over financial reporting in compliance with applicable regulations; (xi) our business could be negatively impacted by increased regulatory scrutiny and litigation; (xii) difficulties associated with retaining, attracting, and training effective employees and management; (xiii) the need to develop innovative products to maintain customer relationships and offset potential price erosion in older products; (xiv) exposure to claims alleging product defects; (xv) the impact of laws and regulations that apply to our business, including those relating to environmental matters, data protection, cyber security and privacy; (xvi) the impact of international laws relating to trade, export controls and foreign corrupt practices; (xvii) changes impacting international trade and corporate tax provisions related to the global manufacturing and sales of our products may have an adverse effect on our financial condition and results of operations; (xviii) volatility of financial and credit markets affecting our access to capital; (xix) default or failure of one or more of our counterparty financial institutions could cause us to incur significant losses; (xx) the need to reduce the total costs of our products to remain competitive; (xxi) potential limitation on the use of net operating losses to offset possible future taxable income; (xxii) restrictions in our debt agreements that could limit our flexibility in operating our business; (xxiii) failure to maintain effective internal controls over financial reporting; (xxiv) service interruption, misappropriation of data, or breaches of security as it relates to our information systems could cause a disruption in our operations, financial losses, and damage to our reputation; (xxv) economic and demographic experience for pension and other post-retirement benefit plans could be less favorable than our assumptions; (xxvi) fluctuation in distributor sales could adversely affect our results of operations; (xxvii) earthquakes, natural disasters, and climate change could disrupt our operations and have a material adverse effect on our financial condition and results of operations; (xxviii) global health epidemics such as the coronavirus could materially affect our business, financial condition, and results of operations; and (xxix) volatility in our stock price.


KEMET CORPORATION AND SUBSIDIARIES

Consolidated Statements of Operations
(Amounts in thousands, except per share data)
(Unaudited)

 
 
Quarter Ended March 31,
 
Fiscal Year Ended March 31,
 
 
2020
 
2019
 
2020
 
2019
Net sales
 
$
293,174
 
 
$
355,794
 
 
$
1,260,554
 
 
$
1,382,818
 
Operating costs and expenses:
 
 
 
 
 
 
 
 
Cost of sales
 
201,165
 
 
229,388
 
 
840,066
 
 
924,276
 
Selling, general and administrative expenses
 
47,523
 
 
53,571
 
 
194,766
 
 
202,642
 
Research and development
 
12,191
 
 
11,572
 
 
49,264
 
 
44,612
 
Restructuring charges
 
2,952
 
 
7,157
 
 
8,882
 
 
8,779
 
Loss on write down of long-lived assets
 
17,615
 
 
49
 
 
19,710
 
 
1,660
 
Total operating costs and expenses
 
281,446
 
 
301,737
 
 
1,112,688
 
 
1,181,969
 
Operating income
 
11,728
 
 
54,057
 
 
147,866
 
 
200,849
 
Non-operating (income) expense:
 
 
 
 
 
 
 
 
Interest income
 
(800
)
 
(710
)
 
(3,325
)
 
(2,035
)
Interest expense
 
2,922
 
 
2,436
 
 
11,021
 
 
21,239
 
Antitrust class action settlements and regulatory costs
 
 
 
2,138
 
 
64,695
 
 
6,701
 
Other (income) expense, net
 
(4,806
)
 
2,430
 
 
(4,356
)
 
4,513
 
Income before income taxes and equity income (loss) from equity method investments
 
14,412
 
 
47,763
 
 
79,831
 
 
170,431
 
Income tax expense (benefit)
 
14,626
 
 
(48,660
)
 
38,526
 
 
(39,460
)
Income before equity income (loss) from equity method investments
 
(214
)
 
96,423
 
 
41,305
 
 
209,891
 
Equity income (loss) from equity method investments
 
(87
)
 
(3,003
)
 
76
 
 
(3,304
)
Net income (loss)
 
$
(301
)
 
$
93,420
 
 
$
41,381
 
 
$
206,587
 
 
 
 
 
 
 
 
 
 
Net income (loss) per basic share
 
$
(0.01
)
 
$
1.60
 
 
$
0.71
 
 
$
3.57
 
Net income (loss) per diluted share
 
$
(0.01
)
 
$
1.58
 
 
$
0.70
 
 
$
3.50
 
 
 
 
 
 
 
 
 
 
Weighted-average shares outstanding:
 
 
 
 
 
 
 
 
Basic
 
58,774
 
 
58,233
 
 
58,574
 
 
57,840
 
Diluted
 
58,774
 
 
58,975
 
 
59,415
 
 
59,082
 


KEMET CORPORATION AND SUBSIDIARIES
Consolidated Balance Sheets
(Amounts in thousands, except per share data)
(Unaudited)

 
 
March 31, 2020
 
March 31, 2019
ASSETS
 
 
 
 
Current assets:
 
 
 
 
Cash and cash equivalents
 
$
222,399
 
 
$
207,918
 
Accounts receivable, net
 
144,743
 
 
154,059
 
Inventories, net
 
243,210
 
 
241,129
 
Prepaid expenses and other current assets
 
36,143
 
 
38,947
 
Total current assets
 
646,495
 
 
642,053
 
Property, plant and equipment, net
 
552,636
 
 
495,280
 
Goodwill
 
41,210
 
 
40,294
 
Intangible assets, net
 
52,713
 
 
53,749
 
Equity method investments
 
16,593
 
 
12,925
 
Deferred income taxes
 
39,750
 
 
57,024
 
Other assets
 
42,226
 
 
16,770
 
Total assets
 
$
1,391,623
 
 
$
1,318,095
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
 
Current liabilities:
 
 
 
 
Current portion of long-term debt
 
$
29,111
 
 
$
28,430
 
Accounts payable
 
103,201
 
 
153,287
 
Accrued expenses
 
167,622
 
 
93,761
 
Income taxes payable
 
2,778
 
 
2,995
 
Total current liabilities
 
302,712
 
 
278,473
 
Long-term debt
 
235,673
 
 
254,771
 
Other non-current obligations
 
191,918
 
 
136,630
 
Deferred income taxes
 
14,058
 
 
8,806
 
Total liabilities
 
744,361
 
 
678,680
 
Stockholders’ equity:
 
 
 
 
Preferred stock, par value $0.01, authorized 10,000 shares, none issued
 
 
 
 
Common stock, par value $0.01, authorized 175,000 shares, issued 58,273 and 57,822 shares at March 31, 2020 and 2019, respectively
 
583
 
 
578
 
Additional paid-in capital
 
474,488
 
 
465,366
 
Retained earnings
 
239,773
 
 
204,195
 
Accumulated other comprehensive income (loss)
 
(67,582
)
 
(30,724
)
Total stockholders’ equity
 
647,262
 
 
639,415
 
Total liabilities and stockholders’ equity
 
$
1,391,623
 
 
$
1,318,095
 


KEMET CORPORATION AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(Amounts in thousands)
(Unaudited)

 
 
Fiscal Years Ended March 31,
 
 
2020
 
2019
Operating activities
 
 
 
 
Net income
 
$
41,381
 
 
$
206,587
 
Adjustments to reconcile net income to net cash provided by (used in) operating activities, net of effect of acquisitions:
 
 
 
 
Depreciation and amortization
 
62,819
 
 
52,628
 
Equity (income) loss from equity method investments
 
(76
)
 
3,304
 
Non-cash debt and financing costs
 
4,173
 
 
1,872
 
Loss on early extinguishment of debt
 
 
 
15,946
 
Stock-based compensation expense
 
12,084
 
 
12,866
 
Pension and other post-retirement benefits
 
6,816
 
 
4,938
 
Change in deferred income taxes
 
25,804
 
 
(49,757
)
Loss on write down of long-lived assets
 
19,710
 
 
1,660
 
Other, net
 
270
 
 
(285
)
Changes in assets and liabilities, net of the effect of acquisitions:
 
 
 
 
Accounts receivable
 
5,727
 
 
(8,910
)
Inventories
 
(3,594
)
 
(42,806
)
Prepaid expenses and other assets
 
3,962
 
 
(4,381
)
Accounts payable
 
(41,442
)
 
7,650
 
Accrued income taxes
 
(236
)
 
1,046
 
Other operating liabilities
 
21,458
 
 
(70,627
)
Net cash provided by (used in) operating activities
 
158,856
 
 
131,731
 
Investing activities:
 
 
 
 
Capital expenditures
 
(146,331
)
 
(146,056
)
Contributions to equity method investments
 
(5,000
)
 
(4,000
)
Proceeds from dividend
 
433
 
 
776
 
Acquisitions, net of cash received
 
(1,294
)
 
 
Proceeds from sale of assets
 
 
 
2,268
 
Net investment hedge settlement
 
8,879
 
 
 
Net cash provided by (used in) investing activities
 
(143,313
)
 
(147,012
)


Consolidated Statements of Cash Flows (Unaudited) (Continued)

 
 
Fiscal Years Ended March 31,
 
 
2020
 
2019
Financing activities:
 
 
 
 
Proceeds from issuance of debt
 
 
 
284,924
 
Payments of long-term debt
 
(26,862
)
 
(344,461
)
Customer advances related to customer capacity agreements
 
43,095
 
 
13,412
 
Proceeds from termination of derivative instruments
 
6,476
 
 
 
Early extinguishment of debt costs
 
 
 
(3,234
)
Debt issuance costs
 
 
 
(2,021
)
Cash flow hedge settlement
 
(6,972
)
 
 
Principal payments on finance leases
 
(1,447
)
 
 
Proceeds from exercise of stock options
 
327
 
 
485
 
Proceeds from exercise of stock warrants
 
 
 
 
Payment of dividends
 
(5,803
)
 
(5,762
)
Net cash provided by (used in) financing activities
 
8,814
 
 
(56,657
)
Net increase (decrease) in cash and cash equivalents
 
24,357
 
 
(71,938
)
Effect of foreign currency fluctuations on cash
 
(1,812
)
 
(6,990
)
Cash, cash equivalents, and restricted cash at beginning of fiscal year
 
207,918
 
 
286,846
 
Cash, cash equivalents, and restricted cash at end of fiscal year
 
230,463
 
 
207,918
 
Less: Restricted cash at end of year
 
8,064
 
 
 
Cash and cash equivalents at end of year
 
$
222,399
 
 
$
207,918
 


Non-GAAP Financial Measures

The Company utilizes certain Non-GAAP financial measures, including “Adjusted gross margin,” “Adjusted SG&A expenses,” “Adjusted operating income,” “Adjusted net income,” “Adjusted net income per basic and diluted share,” “EBITDA,” and “Adjusted EBITDA,” and certain related ratios. Management believes that investors may find it useful to review the Company’s financial results as adjusted to exclude items as determined by management as further described below.

Adjusted Gross Margin

Adjusted gross margin represents net sales less cost of sales excluding adjustments which are outlined in the quantitative reconciliation provided below. Management uses adjusted gross margin to facilitate our analysis and understanding of our business operations by excluding the items outlined in the quantitative reconciliation provided below which might otherwise make comparisons of our ongoing business with prior periods more difficult and obscure trends in ongoing operations. The Company believes that adjusted gross margin is useful to investors because it provides a supplemental way to understand the underlying operating performance of the Company. Adjusted gross margin should not be considered as an alternative to gross margin or any other performance measure derived in accordance with GAAP.

The following table provides a reconciliation from non-GAAP adjusted gross margin to GAAP gross margin, the most directly comparable GAAP measure (amounts in thousands, except percentages):

 
 
Quarters Ended
 
Fiscal Years Ended
 
 
 
 
 
 
 
(Unaudited)
 
 
March 31, 2020
 
December 31, 2019
 
March 31, 2019
 
March 31, 2020
 
March 31, 2019
Net sales
 
$
293,174
 
 
$
294,741
 
 
$
355,794
 
 
$
1,260,554
 
 
$
1,382,818
 
Cost of sales
 
201,165
 
 
201,560
 
 
229,388
 
 
840,066
 
 
924,276
 
Gross Margin (GAAP)
 
92,009
 
 
93,181
 
 
126,406
 
 
420,488
 
 
458,542
 
Gross margin as a % of net sales
 
31.4
%
 
31.6
%
 
35.5
%
 
33.4
%
 
33.2
%
Non-GAAP adjustments:
 
 
 
 
 
 
 
 
 
 
Plant start-up costs
 
233
 
 
136
 
 
(3,346
)
 
369
 
 
(927
)
Stock-based compensation expense
 
1,195
 
 
792
 
 
815
 
 
3,843
 
 
2,756
 
Adjusted gross margin (non-GAAP)
 
$
93,437
 
 
$
94,109
 
 
$
123,875
 
 
$
424,700
 
 
$
460,371
 
Adjusted gross margin as a % of net sales
 
31.9
%
 
31.9
%
 
34.8
%
 
33.7
%
 
33.3
%


Adjusted SG&A Expenses

Adjusted SG&A expenses represents SG&A expenses excluding adjustments which are outlined in the quantitative reconciliation provided below. Management uses adjusted SG&A expenses to facilitate our analysis and understanding of our business operations by excluding these items which might otherwise make comparisons of our ongoing business with prior periods more difficult and obscure trends in ongoing operations. The Company believes that adjusted SG&A expenses is useful to investors because it provides a supplemental way to understand the underlying operating performance of the Company. Adjusted SG&A expenses should not be considered as an alternative to SG&A expenses or any other performance measure derived in accordance with GAAP.

The following table provides a reconciliation from non-GAAP adjusted SG&A expenses to GAAP SG&A expenses, the most directly comparable GAAP measure (amounts in thousands):

 
 
Quarters Ended
 
Fiscal Years Ended
 
 
(Unaudited)
 
 
March 31, 2020
 
December 31, 2019
 
March 31, 2019
 
March 31, 2020
 
March 31, 2019
SG&A expenses (GAAP)
 
$
47,523
 
 
$
50,031
 
 
$
53,571
 
 
$
194,766
 
 
$
202,642
 
Non-GAAP adjustments:
 
 
 
 
 
 
 
 
 
 
ERP integration costs/IT transition costs
 
1,530
 
 
2,029
 
 
3,117
 
 
6,282
 
 
8,813
 
Stock-based compensation expense
 
1,500
 
 
1,521
 
 
1,935
 
 
7,803
 
 
9,751
 
Legal expenses related to antitrust class actions
 
396
 
 
(29
)
 
901
 
 
5,454
 
 
5,195
 
Merger related expenses
 
1,836
 
 
5,283
 
 
 
 
7,119
 
 
 
Contingent consideration fair value adjustment
 
62
 
 
33
 
 
 
 
127
 
 
 
Adjusted SG&A expenses (non-GAAP)
 
$
42,199
 
 
$
41,194
 
 
$
47,618
 
 
$
167,981
 
 
$
178,883
 


Adjusted Operating Income

Adjusted operating income represents operating income, excluding adjustments which are outlined in the quantitative reconciliation provided below. We use adjusted operating income to facilitate our analysis and understanding of our business operations by excluding the items outlined in the quantitative reconciliation provided below, which might otherwise make comparisons of our ongoing business with prior periods more difficult and obscure trends in ongoing operations. The Company believes that adjusted operating income is useful to investors to provide a supplemental way to understand our underlying operating performance and allows investors to monitor and understand changes in our ability to generate income from ongoing business operations. Adjusted operating income should not be considered as an alternative to operating income or any other performance measure derived in accordance with GAAP.

The following table provides a reconciliation from non-GAAP adjusted operating income to GAAP operating income, the most directly comparable GAAP measure (amounts in thousands, except percentages):

 
 
Quarters Ended
 
Fiscal Year Ended
 
 
 
 
 
 
 
(Unaudited)
 
 
March 31, 2020
 
December 31, 2019
 
March 31, 2019
 
March 31, 2020
 
March 31, 2019
Net sales
 
$
293,174
 
 
$
294,741
 
 
$
355,794
 
 
$
1,260,554
 
 
$
1,382,818
 
 
 
 
 
 
 
 
 
 
 
 
Operating income (GAAP)
 
$
11,728
 
 
$
28,648
 
 
$
54,057
 
 
$
147,866
 
 
$
200,849
 
Operating margin as a % of net sales
 
4.0
%
 
9.7
%
 
15.2
%
 
11.7
%
 
14.5
%
Non-GAAP adjustments:
 
 
 
 
 
 
 
 
 
 
Loss on write down of long-lived assets
 
17,615
 
 
1,076
 
 
49
 
 
19,710
 
 
1,660
 
ERP integration costs/IT transition costs
 
1,530
 
 
2,029
 
 
3,117
 
 
6,282
 
 
8,813
 
Stock-based compensation expense
 
2,826
 
 
2,387
 
 
2,855
 
 
12,084
 
 
12,866
 
Restructuring charges
 
2,952
 
 
802
 
 
7,157
 
 
8,882
 
 
8,779
 
Legal expenses related to antitrust class actions
 
396
 
 
(29
)
 
901
 
 
5,454
 
 
5,195
 
Plant start-up costs
 
233
 
 
136
 
 
(3,346
)
 
369
 
 
(927
)
Merger related expenses
 
1,836
 
 
5,283
 
 
 
 
7,119
 
 
 
Contingent consideration fair value adjustment
 
62
 
 
33
 
 
 
 
127
 
 
 
Adjusted operating income (non-GAAP)
 
$
39,178
 
 
$
40,365
 
 
$
64,790
 
 
$
207,893
 
 
$
237,235
 
Adjusted operating margin (non-GAAP) as a % of net sales
 
13.4
%
 
13.7
%
 
18.2
%
 
16.5
%
 
17.2
%


Adjusted Net Income and Adjusted Net Income Per Share

Adjusted net income and adjusted net income per basic and diluted share represent net income (loss) and net income (loss) per basic and diluted share excluding adjustments which are outlined in the quantitative reconciliation provided below. The Company believes that these non-GAAP financial measures are useful to investors because they provide a supplemental way to understand the underlying operating performance of the Company and allow investors to monitor and understand changes in our ability to generate income from ongoing business operations. Management uses these non-GAAP financial measures to evaluate operating performance by excluding the items outlined in the quantitative reconciliation provided below which might otherwise make comparisons of our ongoing business with prior periods more difficult and obscure trends in ongoing operations. Non-GAAP financial measures should not be considered as an alternative to net income (loss), operating income or any other performance measures derived in accordance with GAAP.

The following table provides a reconciliation from non-GAAP adjusted net income and adjusted net income per basic and diluted share to GAAP net income (loss) and GAAP net income (loss) per basic and diluted share, the most directly comparable GAAP measures (amounts in thousands, except per share data):

 
 
Quarters Ended
 
Fiscal Year Ended
 
 
 
 
 
 
 
(Unaudited)
 
 
March 31, 2020
 
December 31, 2019
 
March 31, 2019
 
March 31, 2020
 
March 31, 2019
GAAP
 
 
 
 
 
 
 
 
 
 
Net sales
 
$
293,174
 
 
$
294,741
 
 
$
355,794
 
 
$
1,260,554
 
 
$
1,382,818
 
Net income (loss)
 
$
(301
)
 
$
16,602
 
 
$
93,420
 
 
$
41,381
 
 
$
206,587
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) per basic share
 
$
(0.01
)
 
$
0.28
 
 
$
1.60
 
 
$
0.71
 
 
$
3.57
 
Net income (loss) per diluted share
 
$
(0.01
)
 
$
0.28
 
 
$
1.58
 
 
$
0.70
 
 
$
3.50
 
 
 
 
 
 
 
 
 
 
 
 
Non-GAAP
 
 
 
 
 
 
 
 
 
 
Net income (loss) (GAAP)
 
(301
)
 
16,602
 
 
93,420
 
 
41,381
 
 
206,587
 
Non-GAAP adjustments:
 
 
 
 
 
 
 
 
 
 
Equity (income) loss from equity method investments
 
87
 
 
59
 
 
3,003
 
 
(76
)
 
3,304
 
Loss on write down of long-lived assets
 
17,615
 
 
1,076
 
 
49
 
 
19,710
 
 
1,660
 
Restructuring charges
 
2,952
 
 
802
 
 
7,157
 
 
8,882
 
 
8,779
 
R&D grant reimbursements and grant income
 
(1,572
)
 
(7
)
 
(2
)
 
(1,595
)
 
(4,559
)
ERP integration costs/IT transition costs
 
1,530
 
 
2,029
 
 
3,117
 
 
6,282
 
 
8,813
 
Stock-based compensation
 
2,826
 
 
2,387
 
 
2,855
 
 
12,084
 
 
12,866
 
Settlements, regulatory costs, and legal expenses related to antitrust class actions
 
396
 
 
1,568
 
 
3,039
 
 
70,149
 
 
11,896
 
Net foreign exchange (gain) loss
 
(8,089
)
 
4,113
 
 
2,316
 
 
(6,762
)
 
(7,230
)
Plant start-up costs
 
233
 
 
136
 
 
(3,346
)
 
369
 
 
(927
)
Income tax effect of non-GAAP adjustments
 
2,134
 
 
(5,693
)
 
(50,208
)
 
(22,085
)
 
(50,012
)
(Gain) loss on early extinguishment of debt
 
 
 
 
 
(42
)
 
 
 
15,946
 
Write off of debt issuance costs
 
453
 
 
 
 
 
 
453
 
 
 
Merger related expenses
 
1,836
 
 
5,283
 
 
 
 
7,119
 
 
 
Curtailment/settlement expense on defined benefit pension plans
 
1,949
 
 
 
 
 
 
1,949
 
 
 
Unrealized (gain) loss on equity securities
 
89
 
 
(794
)
 
 
 
(705
)
 
 
Contingent consideration fair value adjustment
 
62
 
 
33
 
 
 
 
127
 
 
 
Adjusted net income (non-GAAP)
 
$
22,200
 
 
$
27,594
 
 
$
61,358
 
 
$
137,282
 
 
$
207,123
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted net income per basic share (non-GAAP)
 
$
0.38
 
 
$
0.47
 
 
$
1.05
 
 
$
2.34
 
 
$
3.58
 
Adjusted net income per diluted share (non-GAAP)
 
$
0.37
 
 
$
0.46
 
 
$
1.04
 
 
$
2.31
 
 
$
3.51
 
 
 
 
 
 
 
 
 
 
 
 
Weighted average shares outstanding:
 
 
 
 
 
 
 
 
 
 
Basic
 
58,774
 
 
58,646
 
 
58,233
 
 
58,574
 
 
57,840
 
Diluted (1)
 
59,612
 
 
59,529
 
 
58,975
 
 
59,415
 
 
59,082
 

_________________________________________
(1) For the quarter ended March 31, 2020, diluted shares were used to compute adjusted net income per diluted share (non-GAAP).


EBITDA and Adjusted EBITDA

EBITDA represents net income before income tax expense, interest expense, net, and depreciation and amortization expense. We present EBITDA as a supplemental measure of our ability to service debt. We believe EBITDA is an appropriate supplemental measure of debt service capacity because cash expenditures on interest are, by definition, available to pay interest, and tax expense is inversely correlated to interest expense because tax expense goes down as deductible interest expense goes up; and depreciation and amortization are non-cash charges.

We also present adjusted EBITDA, which is EBITDA excluding adjustments that are outlined in the following quantitative reconciliation provided, as a supplemental measure of our performance and because we believe this measure is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. The items excluded from adjusted EBITDA are excluded in order to better reflect our continuing operations.

In evaluating adjusted EBITDA, you should be aware that in the future we may incur expenses similar to the adjustments noted below. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these types of adjustments. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income, operating income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as a measure of our liquidity.

Our adjusted EBITDA measure has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

  • it does not reflect our cash expenditures, future requirements for capital expenditures or contractual commitments;
  • it does not reflect changes in, or cash requirements for, our working capital needs;
  • it does not reflect the significant interest expense or the cash requirements necessary to service interest or principal payments on our debt;
  • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and our adjusted EBITDA measure does not reflect any cash requirements for such replacements;
  • it is not adjusted for all non-cash income or expense items that are reflected in our statements of cash flows;
  • it does not reflect the impact of earnings or charges resulting from matters we consider not to be indicative of our ongoing operations;
  • it does not reflect limitations on or costs related to transferring earnings from our subsidiaries to us; and
  • other companies in our industry may calculate this measure differently than we do, limiting its usefulness as a comparative measure.

Because of these limitations, adjusted EBITDA should not be considered as a measure of discretionary cash available to us to invest in the growth of our business or as a measure of cash that will be available to us to meet our obligations. You should compensate for these limitations by relying primarily on our GAAP results and using adjusted EBITDA as supplementary information.

The following tables provides a reconciliation from EBITDA, non-GAAP adjusted EBITDA, and non-GAAP adjusted EBITDA margin to GAAP net income (loss), the most directly comparable GAAP measure (amounts in thousands, except percentages):

 
 
Fiscal Year 2020
 
 
Q1
 
Q2
 
Q3
 
Q4
 
Total
 
 
(Unaudited)
Net Sales
 
$
345,242
 
 
$
327,397
 
 
$
294,741
 
 
$
293,174
 
 
$
1,260,554
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss) (GAAP)
 
$
40,340
 
 
$
(15,260
)
 
$
16,602
 
 
$
(301
)
 
$
41,381
 
Net income (loss) margin as a % of net sales
 
11.7
%
 
(4.7
)%
 
5.6
%
 
(0.1
)%
 
3.3
%
Non-GAAP adjustments:
 
 
 
 
 
 
 
 
 
 
Income tax expense (benefit)
 
16,800
 
 
1,700
 
 
5,400
 
 
14,626
 
 
38,526
 
Interest expense, net
 
1,736
 
 
1,939
 
 
1,899
 
 
2,122
 
 
7,696
 
Depreciation and amortization
 
14,259
 
 
15,117
 
 
16,154
 
 
17,289
 
 
62,819
 
EBITDA (non-GAAP)
 
73,135
 
 
3,496
 
 
40,055
 
 
33,736
 
 
150,422
 
Excluding the following items:
 
 
 
 
 
 
 
 
 
 
Equity (income) loss from equity method investments
 
250
 
 
(472
)
 
59
 
 
87
 
 
(76
)
Loss on write down of long-lived assets
 
960
 
 
59
 
 
1,076
 
 
17,615
 
 
19,710
 
ERP integration costs/IT transition costs
 
1,215
 
 
1,508
 
 
2,029
 
 
1,530
 
 
6,282
 
Stock-based compensation
 
2,725
 
 
4,146
 
 
2,387
 
 
2,826
 
 
12,084
 
Restructuring charges
 
2,208
 
 
2,920
 
 
802
 
 
2,952
 
 
8,882
 
R&D grant reimbursements and grant income
 
(35
)
 
19
 
 
(7
)
 
(1,572
)
 
(1,595
)
Settlements, regulatory costs, and legal expenses related to antitrust class actions
 
2,559
 
 
65,626
 
 
1,568
 
 
396
 
 
70,149
 
Net foreign exchange (gain) loss
 
(489
)
 
(2,297
)
 
4,113
 
 
(8,089
)
 
(6,762
)
Plant start-up costs
 
34
 
 
(34
)
 
136
 
 
233
 
 
369
 
Write off of debt issuance costs
 
 
 
 
 
 
 
453
 
 
453
 
Merger related expenses
 
 
 
 
 
5,283
 
 
1,836
 
 
7,119
 
Curtailment/settlement expense on defined benefit pension plans
 
 
 
 
 
 
 
1,949
 
 
1,949
 
Unrealized (gain) loss on equity securities
 
 
 
 
 
(794
)
 
89
 
 
(705
)
Contingent consideration fair value adjustment
 
 
 
32
 
 
33
 
 
62
 
 
127
 
Adjusted EBITDA (non-GAAP)
 
$
82,562
 
 
$
75,003
 
 
$
56,740
 
 
$
54,103
 
 
$
268,408
 
Adjusted EBITDA margin (non-GAAP) as a % of net sales
 
23.9
%
 
22.9
%
 
19.3
%
 
18.5
%
 
21.3
%


 
 
Fiscal Year 2019
 
 
Q1
 
Q2
 
Q3
 
Q4
 
Total
 
 
(Unaudited)
Net Sales
 
$
327,616
 
 
$
349,233
 
 
$
350,175
 
 
$
355,794
 
 
$
1,382,818
 
 
 
 
 
 
 
 
 
 
 
 
Net income (GAAP)
 
$
35,220
 
 
$
37,141
 
 
$
40,806
 
 
$
93,420
 
 
$
206,587
 
Net income (loss) margin as a % of net sales
 
10.8
%
 
10.6
%
 
11.7
%
 
26.3
%
 
14.9
%
Non-GAAP-adjustments:
 
 
 
 
 
 
 
 
 
 
Income tax expense (benefit)
 
4,600
 
 
2,000
 
 
2,600
 
 
(48,660
)
 
(39,460
)
Interest expense, net
 
6,658
 
 
6,912
 
 
3,908
 
 
1,726
 
 
19,204
 
Depreciation and amortization
 
13,097
 
 
12,545
 
 
12,763
 
 
14,223
 
 
52,628
 
EBITDA (non-GAAP)
 
59,575
 
 
58,598
 
 
60,077
 
 
60,709
 
 
238,959
 
Excluding the following items:
 
 
 
 
 
 
 
 
 
 
Equity (income) loss from equity method investments
 
69
 
 
(64
)
 
296
 
 
3,003
 
 
3,304
 
Loss on write down of long-lived assets
 
511
 
 
312
 
 
788
 
 
49
 
 
1,660
 
ERP integration costs/IT transition costs
 
1,650
 
 
1,593
 
 
2,453
 
 
3,117
 
 
8,813
 
Stock-based compensation
 
4,060
 
 
4,417
 
 
1,534
 
 
2,855
 
 
12,866
 
Restructuring charges
 
(96
)
 
 
 
1,718
 
 
7,157
 
 
8,779
 
R&D grant reimbursements and grant income
 
(4,087
)
 
 
 
(470
)
 
(2
)
 
(4,559
)
Settlements, regulatory costs, and legal expenses related to antitrust class actions
 
1,248
 
 
6,060
 
 
1,549
 
 
3,039
 
 
11,896
 
Net foreign exchange (gain) loss
 
(7,521
)
 
193
 
 
(2,218
)
 
2,316
 
 
(7,230
)
Plant start-up costs
 
753
 
 
1,361
 
 
305
 
 
(3,346
)
 
(927
)
(Gain) loss on early extinguishment of debt
 
 
 
 
 
15,988
 
 
(42
)
 
15,946
 
Adjusted EBITDA (non-GAAP)
 
$
56,162
 
 
$
72,470
 
 
$
82,020
 
 
$
78,855
 
 
$
289,507
 
Adjusted EBITDA margin (non-GAAP) as a % of net sales
 
17.1
%
 
20.8
%
 
23.4
%
 
22.2
%
 
20.9
%


Contact:
Gregory C. Thompson
Richard Vatinelle
 
Executive Vice President and
Vice President and
 
Chief Financial Officer
Treasurer
 
GregThompson@KEMET.com
InvestorRelations@KEMET.com
 
954-595-5081
954-766-2819


Stock Information

Company Name: KEMET Corporation
Stock Symbol: KEM
Market: NYSE
Website: kemet.com

Menu

KEM KEM Quote KEM Short KEM News KEM Articles KEM Message Board
Get KEM Alerts

News, Short Squeeze, Breakout and More Instantly...